
    
      This is a randomized, double-blind, two-group parallel, placebo-controlled clinical Phase III
      trial.

      The primary objective is to evaluate the effect of QL1206 treatment compared with placebo in
      Chinese postmenopausal women with osteoporosis at high risk of fracture.

      The secondary objective is to evaluate the clinical safety, immunogenicity and
      pharmacokinetic (PK) characteristics of QL1206 in women with osteoporosis at high risk of
      postmenopausal fracture

      The exploratory purpose is to evaluate the effect of ADA on the characteristics of QL1206 PK
      and the relationship between QL1206 exposure and pharmacodynamic endpoints, efficacy and
      adverse events

      Subjects would sequentially enrolled according to the protocol in one of two cohorts.Subjects
      would receive a single 60mg of QL1206 or placebo every 6 month for1 year(twice for one,
      subcutaneous injection) ,meanwhile taking 500 mg of calcium and 1000IU of vitamin D daily
    
  